Compound Radar

Tango Therapeutics, Inc. (TNGX) Stock Analysis

United States · Healthcare / Biotechnology

Price $22.70
Market cap $3.83B
Next earnings Nov 4, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

41
41/100 Avoid
  • Financial Health 55
  • Profitability 70
  • Business Quality 50
  • Balance Sheet 55
  • Cash Flow 60

Why this rating?

Health 41/100 — Avoid

Strongest Profitability 70/100
Softest Business Quality 50/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Tango Therapeutics, Inc. (TNGX) is a Biotechnology company in the Healthcare sector. Compound Radar rates Tango Therapeutics, Inc. 41/100 (Avoid) due to solid business quality.

Investment profile

  • Quality Moderate
  • Balance Sheet Unknown

Financial highlights

Valuation

  • Forward P/E -13.61
  • EV/Revenue 52.32

Profitability

  • Gross Margin -148.4%
  • Operating Margin -253.4%
  • Net Margin -229.9%
  • ROE -21.3%

Financial strength

  • Cash $1.01B
  • Debt $31.99M
  • Net Cash $982.00M
  • Free Cash Flow $-139.93M
  • Current Ratio 50.82

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Tango Therapeutics, Inc. (TNGX).

View Methodology & FAQ →